8-K: Palatin Technologies Announces Positive Phase 3 Trial Results and Provides Corporate Update

Palatin Technologies reports positive results from its Phase 3 MELODY-1 trial for dry eye disease, along with updates on other clinical programs and financial results for the third quarter of fiscal year 2024.

Summary

• Palatin Technologies announced its financial results for the third quarter of fiscal year 2024, ending March 31, 2024.
• The company's Phase 3 MELODY-1 trial for PL9643 in dry eye disease met its co-primary symptom endpoint of pain with statistical significance (P<0.025).
• Seven out of eleven secondary symptom endpoints also achieved statistical significance (P<0.05) at the 12-week treatment period.
• Multiple symptom endpoints, including the co-primary pain endpoint, showed statistical significance (P<0.05) as early as the 2-week treatment period.
• The trial demonstrated an excellent safety and tolerability profile for PL9643.
• Palatin is planning a Type C meeting with the FDA in the third quarter of calendar year 2024 to discuss the remaining studies for PL9643.
• The company is targeting an NDA submission for PL9643 in the second half of calendar year 2025.
• Palatin expects an interim analysis for its Phase 2 PL8177 oral formulation for ulcerative colitis in the second quarter of calendar year 2024, with topline results in the second half of the year.
• A Phase 2 clinical study of a MCR4 agonist plus a GLP-1 for obesity is targeted to start in the second quarter of calendar year 2024.
• A Phase 2 clinical study of bremelanotide co-formulated with a PDE5i for erectile dysfunction is also targeted to start in the second quarter of calendar year 2024.
• Palatin completed a registered direct offering on February 1, 2024, raising $10 million in gross proceeds.
• The company's net loss for the quarter was $8.4 million, or $(0.53) per share, compared to a net loss of $8.7 million, or $(0.76) per share, for the same period last year.
• As of March 31, 2024, Palatin's cash, cash equivalents, and marketable securities totaled $10.0 million.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and progress in multiple therapeutic areas, along with a successful capital raise. However, the company is still operating at a loss and has limited cash reserves, which tempers the overall sentiment.

Positives

• The Phase 3 MELODY-1 trial for PL9643 in dry eye disease showed statistically significant results for both primary and multiple secondary endpoints.
• PL9643 demonstrated a rapid onset of efficacy, with significant results as early as two weeks.
• The safety and tolerability profile of PL9643 was excellent.
• Palatin is advancing discussions with potential collaboration partners for PL9643.
• The company is launching two new Phase 2 clinical trials in the second quarter of calendar year 2024, expanding its pipeline.
• Palatin successfully raised $10 million through a registered direct offering.

Negatives

• Palatin's net loss for the quarter was $8.4 million.
• The company's cash used in operations increased to $8.6 million compared to $1.4 million for the same period last year.
• Palatin did not record any product sales for the quarter ended March 31, 2024, due to the sale of Vyleesi rights.

Risks

• The company's ability to fund the development of its technology and complete clinical trials is subject to risks.
• Regulatory actions by the FDA and other agencies could impact the approval of Palatin's products.
• The company faces competition from other pharmaceutical and biotechnology companies.
• Commercial acceptance of Palatin's products is not guaranteed.
• The company's cash position is $10 million, which is expected to fund operations into the second half of calendar year 2024, indicating a potential need for additional funding.

Future Outlook

Palatin believes that its existing cash, cash equivalents, marketable securities, and accounts receivable will be sufficient to fund currently anticipated operating expenses and disbursements into the second half of calendar year 2024. The company is also targeting an NDA submission for PL9643 in the second half of calendar year 2025.

Management Comments

• Carl Spana, Ph.D., President and Chief Executive Officer of Palatin, stated that the efficacy results of the MELODY-1 trial were statistically significant for the co-primary symptom endpoint of pain and 7 of 11 exploratory secondary endpoints, including eye dryness, as early as two weeks.
• Dr. Spana also mentioned that they are advancing discussions with potential collaboration partners and actively preparing for a meeting with the FDA later this year.
• Dr. Spana commented that they are excited to launch two new therapeutic area clinical trials in the second quarter of calendar year 2024.

Industry Context

The positive results from the MELODY-1 trial for dry eye disease position Palatin as a potential competitor in the ophthalmology market. The company's focus on melanocortin receptor agonists also aligns with the growing interest in novel therapeutic approaches for various conditions, including obesity and sexual dysfunction. The combination therapy approach for obesity and erectile dysfunction is also a growing trend in the pharmaceutical industry.

Comparison to Industry Standards

• The MELODY-1 trial results for PL9643 are promising compared to existing dry eye disease treatments, particularly with the rapid onset of efficacy and multiple symptom improvements.
• Companies like Allergan (now AbbVie) with Restasis and Xiidra have established a market for dry eye treatments, but PL9643's unique mechanism of action and early efficacy could provide a competitive advantage.
• In the obesity space, the combination of MCR4 agonists with GLP-1 therapies is an emerging area, with companies like Eli Lilly and Novo Nordisk leading the GLP-1 market. Palatin's approach could offer a differentiated option.
• For erectile dysfunction, the combination of bremelanotide with PDE5 inhibitors is a novel approach, as current treatments primarily focus on PDE5 inhibitors alone. Companies like Pfizer with Viagra and Eli Lilly with Cialis dominate this market, but Palatin's combination therapy could address the unmet need of non-responders.

Stakeholder Impact

• Shareholders may view the positive clinical trial results and capital raise favorably.
• Employees may be encouraged by the progress of the company's pipeline.
• Patients with dry eye disease, obesity, and erectile dysfunction may benefit from the development of new treatment options.
• Potential collaboration partners may be interested in the promising results of PL9643.

Next Steps

• Palatin will hold a Type C meeting with the FDA in the third quarter of calendar year 2024 to discuss the remaining studies for PL9643.
• The company plans to initiate MELODY-2 and MELODY-3 trials in the second half of calendar year 2024.
• An NDA submission for PL9643 is targeted for the second half of calendar year 2025.
• Interim analysis for the Phase 2 PL8177 trial is expected in the second quarter of calendar year 2024.
• Topline data readouts for the PL8177 trial, the obesity trial, and the erectile dysfunction trial are expected in the second half of calendar year 2024.
• Initiation of investigational new drug (IND) enabling activities for a novel MCR4 selective long-acting agonist is expected in the second half of calendar 2024.

Key Dates

Keywords

Palatin Technologies, PL9643, Dry Eye Disease, MELODY-1, Clinical Trial, Melanocortin Receptor, Obesity, Erectile Dysfunction, Bremelanotide, Ulcerative Colitis, FDA, Phase 3, Phase 2, Financial Results